GLB 001
Alternative Names: GLB-001; GLB-C183-A-2Latest Information Update: 20 Jun 2024
At a glance
- Originator GluBio Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
Most Recent Events
- 24 May 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (PO) (NCT06378437)
- 24 May 2024 Phase-I clinical trials in Essential thrombocythaemia (Treatment-experienced) in China (PO) (NCT06378437)
- 24 May 2024 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in China (PO) (NCT06378437)